MiniMed Group (MMED): Can It Reach the +27% Upside to $25 Analyst Target?
Key Takeaways
- Price Target: $25 represents a roughly 27.5% upside from the current price near $19.60 and sits at the top of Wall Street's 12-month analyst target range.
- Bull Case: Multiple prominent firms — including BTIG, UBS, and Wells Fargo — have assigned price targets at or above $25, citing double-digit revenue growth, expanding margins, and a rapidly growing $18 billion global diabetes technology market.
- Bear Case: The company remains deeply unprofitable with a net loss of $333 million in fiscal 2026, recently missed earnings expectations, and faces intense competition from established rivals in the insulin pump and continuous glucose monitoring (CGM) space.
- Key Resistance: The 52-week high of $20.48 represents the first major hurdle; a breakout above that level would mark uncharted territory for the stock.
- Key Support: The $15–$16 zone has served as a significant demand area and aligns with Piper Sandler's conservative $16 price target.
- Bottom Line: Reaching $25 is plausible within a 12-to-18-month horizon but requires successful execution across multiple product launches and a clear path toward profitability.
Why the $25 Level Stands Out
The $25 price target has emerged as a widely discussed milestone because it represents the high-water mark among Wall Street analyst estimates. BTIG reiterated its $25 target in July 2026, basing its valuation on roughly 9x to 10x forward enterprise value-to-adjusted EBITDA. UBS Group initiated coverage with a Buy rating and a $25 target in late July, while Wells Fargo raised its target to $26 in June. Goldman Sachs set a nearby $24 target earlier in the year. With the stock trading just below $20, the $25 level has become the focal point of the debate around MiniMed Group's growth trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
A Closer Look at MiniMed Group
MiniMed Group is a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of diabetes management solutions. Its platform includes Automated Insulin Delivery (AID) systems — insulin pumps, CGM sensors, and algorithms that work together to mimic a healthy pancreas — as well as Smart Multiple Daily Injection (MDI) systems featuring smart insulin pens. The company generates revenue across more than 80 countries and posted $3.10 billion in sales during fiscal 2026, representing 14.3% year-over-year growth. International markets accounted for roughly 70% of total revenue, growing at a 20.6% reported rate. The company holds more than 2,000 patents and operates as the only full-stack provider in the diabetes technology space — meaning it owns the pump, sensor, algorithm, and software ecosystem under one roof.
Catalysts That Could Support Higher Prices
Several catalysts could power the stock toward the $25 mark. The MiniMed Flex system, a next-generation smartphone-controlled insulin pump that received FDA clearance ahead of schedule, launched commercially in the United States in June 2026. This product represents the company's smallest and most discreet pump yet and could help recapture U.S. market share after years of stagnation — U.S. sales grew just 1.5% in fiscal 2026.
International momentum remains strong, with organic revenue growth of 11.2% outside the United States. The recent launch of Instinct sensors in Europe, developed through a partnership with ABT, expands sensor choice for patients. Meanwhile, the MiniMed Go smart MDI platform and the Fit patch pump — currently in development — represent additional growth vectors that could accelerate revenue over the next two years.
Wall Street expects MiniMed to approach profitability inflection. Analyst consensus projects adjusted EPS of approximately $0.65 for fiscal 2027, a dramatic swing from the -$1.30 loss per share reported in fiscal 2026. If the company delivers on margin expansion targets — moving adjusted EBITDA margins from the mid-teens toward 25% over several years — the valuation case for $25 strengthens considerably.
The underlying market tailwind is also significant. The global diabetes technology market is valued at over $18 billion and growing at a high-teens percentage rate, yet remains only about 7% penetrated. Rising diabetes prevalence worldwide provides a durable secular growth backdrop. From what I see, the product pipeline offers tangible near-term drivers.
Risks That Could Slow Progress
Despite the optimistic analyst consensus, meaningful risks stand between MiniMed and the $25 target. The company's latest quarterly report underscored these challenges: MiniMed posted a loss of $0.68 per share, missing consensus estimates by a wide margin, despite delivering $837 million in revenue that beat expectations. Net losses widened from $213 million in fiscal 2025 to $333 million in fiscal 2026.
Competition remains fierce. DXCM and ABT dominate the CGM market, while PODD leads in the patch pump category. MiniMed's U.S. pump sales have been essentially flat, with approximately 145,000 new pumps sold worldwide in fiscal 2026 — unchanged from the prior year. Regaining momentum in its home market is essential for the stock to command a higher valuation multiple.
Additionally, Medtronic (MDT) retains a roughly 90% ownership stake following the IPO, meaning the public float is relatively small and the stock may face ongoing overhang risk if Medtronic decides to distribute or sell additional shares.
Analyst Views and Price Targets
The analyst community is broadly bullish but with a range that reflects genuine uncertainty. Of 12 to 13 analysts covering the stock, the overwhelming majority rate it a Buy or equivalent. The consensus 12-month price target sits near $21, representing about 7% upside from current levels. However, the range is wide: Piper Sandler maintains a Hold rating with a $16 target, while BTIG, UBS, and Wells Fargo see $25 to $26 as achievable. This dispersion highlights that the $25 level is an optimistic but credible scenario — not the base case for the broader analyst community.
Key Technical Levels to Watch
From a technical standpoint, MiniMed shares have been in a strong recovery trend since bottoming at $10.65 in May 2026. The rally has pushed the stock toward its 52-week high of $20.48, an area that now represents the first critical resistance zone. A decisive breakout above $20.48 on strong volume would confirm that buyers are willing to absorb supply at all-time highs — a necessary precondition for a sustained move toward $25.
On the downside, the $15–$16 area has acted as reliable support, reinforced by the 50-day moving average and Piper Sandler's conservative price target. A breakdown below this zone would invalidate the near-term bullish thesis. The psychological round number of $20 also serves as an important battleground where buyers and sellers are currently contending for control. I’m watching these levels closely as the stock approaches critical junctures.
Enhancing Analysis with Tickeron Tools
In my own process, I frequently use Tickeron’s AI Daily Buy/Sell Signals to monitor stocks like this one. The platform applies artificial intelligence to scan thousands of securities and deliver timely Buy, Sell, or Hold signals based on technical patterns and market conditions. This helps me stay objective when evaluating potential moves around key levels such as $20.48 resistance or $15–$16 support, complementing traditional research without replacing it.
Final Assessment
The question of whether MiniMed Group can reach $25 hinges on execution. The company operates in a large, underpenetrated market with genuine competitive advantages as the only full-stack diabetes technology provider. Multiple respected Wall Street firms have placed $25 targets on the stock, and the product pipeline — including MiniMed Flex, Go, Fit, and new sensor integrations — provides concrete catalysts that could drive revenue growth and margin expansion over the next 12 to 18 months.
However, the path to $25 is far from guaranteed. Persistent unprofitability, flat U.S. pump adoption, intense competitive pressure, and a recent history of earnings misses argue for caution. The stock must first clear the $20.48 all-time high before $25 becomes a realistic near-term objective. Investors should monitor upcoming earnings reports, U.S. commercial execution of MiniMed Flex, and any updates to Medtronic's ownership position as key signposts on the road to $25.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MMED sees its Stochastic Oscillator ascends from oversold territory
On October 09, 2026, the Stochastic Oscillator for MMED moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 4 instances where the indicator left the oversold zone. In 4 of the 4 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMED advanced for three days, in 28 of 31 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for MMED moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 similar instances where the indicator moved out of overbought territory. In 2 of the 3 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMED as a result. In 1 of 5 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 20%.
The Moving Average Convergence Divergence Histogram (MACD) for MMED turned negative on September 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 5 similar instances when the indicator turned negative. In 3 of the 5 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for MMED entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.593) is normal, around the industry mean (5.011). P/E Ratio (0.000) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.950) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement